NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $80,000 | -38.5% | 25,061 | -25.9% | 0.01% | -30.0% |
| Q2 2022 | $130,000 | -45.8% | 33,810 | -23.1% | 0.01% | -37.5% |
| Q1 2022 | $240,000 | -56.4% | 43,943 | +8.3% | 0.02% | -54.3% |
| Q4 2021 | $550,000 | +1.9% | 40,593 | +35.7% | 0.04% | -7.9% |
| Q3 2021 | $540,000 | +12.5% | 29,923 | +6.6% | 0.04% | +15.2% |
| Q2 2021 | $480,000 | -11.1% | 28,058 | +3.1% | 0.03% | -17.5% |
| Q1 2021 | $540,000 | +25.6% | 27,208 | +8.8% | 0.04% | +17.6% |
| Q4 2020 | $430,000 | +13.2% | 25,008 | +9.0% | 0.03% | 0.0% |
| Q3 2020 | $380,000 | -26.9% | 22,938 | +2.2% | 0.03% | -32.0% |
| Q2 2020 | $520,000 | +55.2% | 22,435 | +19.4% | 0.05% | +28.2% |
| Q1 2020 | $335,000 | -1.2% | 18,785 | +19.5% | 0.04% | +25.8% |
| Q4 2019 | $339,000 | – | 15,720 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |